(Total Views: 447)
Posted On: 09/24/2018 4:57:57 PM
Post# of 72441
more interesting .. (at least to me) is the volume done on AMRN .. and what it reveals (currently and over the coming weeks)
Detailed Quote:AMRN
AMARIN CORP PLC
12.40Up 9.41 (314.72 %)AS OF 4:00:00PM ET 09/24/2018
Last Trade 12.40
Trade Time 4:00:00pm ET
Change 9.41
% Change 314.72%
Bid 12.52
Bid Size 2
Ask 12.57
Ask Size 1
Open 10.44
Day High 12.47
Day Low 9.51
Previous Close
09/21/2018 2.99
52-Week High
09/24/2018 12.47
52-Week Low
07/31/2018 2.35
Price Performance (Last 52 Weeks)
09/21/2018 -7.72%
Volume 162,445,938
Volume (10 day Average) 3,543,201
Volume (90 day Average) 2,944,746
Options Yes
Market Capitalization $886.08M
Shares Outstanding 296,349,000
4kids
Detailed Quote:AMRN
AMARIN CORP PLC
12.40Up 9.41 (314.72 %)AS OF 4:00:00PM ET 09/24/2018
Last Trade 12.40
Trade Time 4:00:00pm ET
Change 9.41
% Change 314.72%
Bid 12.52
Bid Size 2
Ask 12.57
Ask Size 1
Open 10.44
Day High 12.47
Day Low 9.51
Previous Close
09/21/2018 2.99
52-Week High
09/24/2018 12.47
52-Week Low
07/31/2018 2.35
Price Performance (Last 52 Weeks)
09/21/2018 -7.72%
Volume 162,445,938
Volume (10 day Average) 3,543,201
Volume (90 day Average) 2,944,746
Options Yes
Market Capitalization $886.08M
Shares Outstanding 296,349,000
4kids
Quote:
Interesting speculation by CITI on AMRN today:
Citi sees another 5x upside in Amarin
Sep. 24, 2018 11:53 AM ET|By: Stephen Alpher, SA News Editor
Amarin (NASDAQ:AMRN) has skyrocketed more than 200% to $10.15 today after its fish oil capsule showed big benefits in a trial of more than 8K patients with elevated risk of heart issues.
Assuming the expanded REDUCE-IT label is granted, Citi sees peak sales of a whopping $2.7B. That assumes only about 2M of the 50B-70B eligible patients are treated. The team there sees upside to $50 per share, with Amarin being a strong acquisition target. Source: Notable Calls
Also on the move on the news is Acasti Pharma (ACST +26.9%), whose heart pill candidate CaPre is mostly made up of omega-3 fatty acids.
Previously: Amarin reports positive results from REDUCE-IT study; shares up 307% premarket (Sept. 24)
If they are worth $50.00 in a buyout with a single drug just imagine what we will be worth with multiple blockbusters! Just goes to show how undervalued we are at this time. Go IPIX!!!
(2)
(0)
Scroll down for more posts ▼